A Phase II Study of Glembatumumab Vedotin for Metastatic Uveal Melanoma

A Phase II Study of Glembatumumab Vedotin for Metastatic Uveal Melanoma

Glembatumumab vedotin (CDX-011, GV) is a fully human Immunoglobulin G2 monoclonal antibody directed against glycoprotein NMB coupled via a peptide linker to monomethyl auristatin E (MMAE), a potent cytotoxic microtubule inhibitor. This phase II study evaluated the overall response rate and safety of...

Full description

Bibliographic Details
Main Authors: Merve Hasanov, Matthew J. Rioth, Kari Kendra, Leonel Hernandez-Aya, Richard W. Joseph, Stephen Williamson, Sunandana Chandra, Keisuke Shirai, Christopher D. Turner, Karl Lewis, Elizabeth Crowley, Jeffrey Moscow, Brett Carter, Sapna Patel
Format: Article
Language:English
Published: MDPI AG 2020-08-01
Series:Cancers
Subjects:
uveal melanoma
glembatumumab vedotin
phase II
clinical trial
Online Access:https://www.mdpi.com/2072-6694/12/8/2270

Internet

https://www.mdpi.com/2072-6694/12/8/2270

Similar Items